Ivacaftor gains licence extension in EU

Ivacaftor has now been approved for use in children 6 months and older, and at least 5kg in weight, who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Around 500 children with cystic fibrosis have this specific mutation in the EU.